SLC31A1 and breast carcinoma: In the present study, SLC31A1 expression was significantly decreased in non-response groups with respect to response groups, when breast cancer patients were treated with conventional chemotherapy regimens including FEC plus docetaxel, TA, and FEC plus paclitaxel.